Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options
Healthcare providers trained to recognize this triad may miss patients with incomplete or evolving symptom patterns
Experimental GPX1 deficiency amplifies certain aspects of aging, namely endothelial dysfunction, vascular remodeling, and invasion of leukocytes in cardiovascular tissue
This product is not approved by the FDA and is not intended for human or veterinary use
US$ 27.52
US$ 22.17
US$ 23.60
US$ 27.93
US$ 28.57